I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Sangamo Therapeutics (SGMO) proposes $72.5 M offering

June 20, 2017

SGMO closes UP +$0.25 to $8.20 and promptly dives -$0.70 or -8.54% to $7.50 ​SGMO prices 10 M shares at $7.25  

Fibrocell Science (FCSC) gets “Rare Pediatric Disease Designation” from FDA

June 12, 2017

FCSC is up +$0.23 or +9.27% in the pre-market, it's a BUY with an exit defined in short timing ... news has a life cycle in this market